BELGRADE, Mont., Aug. 03, 2017 -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, is proud to announce its sponsorship of the 2018 Donate Life float at the January 1 Rose Parade® in Pasadena. The Donate Life float, now in its 15th year, is part of a national effort of more than 50 organizations that have teamed up to deliver the simple, life giving message that the kind and generous act of becoming a donor helps save and heal lives. This will be the 7th year Xtant Medical has supported the float, in an effort to showcase the importance and power of organ, eye and tissue donation.
|
|||||
An image accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/4fb9c956-b9af-4504-a936-680572ee0333
"With nearly 120,000 people currently waiting for a lifesaving transplant, it is our hope that this float will help bring worldwide attention to the need for more people to register to be donors and, by doing so, make an impact in the lives of others," said Carl O’Connell, CEO. "We are excited to showcase the stories of our participants who have truly made a difference in their communities, by sharing the gift of time with others, whether they are living donors, donor families, or recipients."
This year’s float entry, The Gift of Time, reflects the parade’s theme of Making a Difference, by celebrating the kindness of people throughout the world who are making a positive difference in the lives of others. Perhaps no act is more emblematic of this than becoming an organ, eye or tissue donor: a single organ donor can save the lives of up to eight people, and improve the lives of as many as 75 more by donating their corneas and tissue.
"The ultimate gift anyone can give is the gift of time," said Tom Mone, chairman of the Donate Life Rose Parade® float committee and CEO of OneLegacy, the world’s largest nonprofit organ, eye and tissue recovery organization. "We are deeply grateful to all of our Donate Life Rose Parade® float sponsors, who are helping us spread the word about the importance of donation on one of the biggest stages in the world, the Tournament of Roses® Parade. Our sponsors’ continuous and unconditional work within their communities empowers organ, eye and tissue recipients, as well as donor families to share their stories and inspire others to register."
The Gift of Time float depicts a vibrantly colored, tropical backdrop that dates back to the ancient civilizations of Mexico. It celebrates the gift of life as transplant recipients sit against stone carvings which reflect the strength they have gained from their donors to continue and thrive on life’s journey. The float will also feature floragraphs honoring 44 donors while eight living donors and recipients walk alongside the float carrying baskets of fruit and flowers in celebration of the renewed life they have shared with one another and the world.
As the world’s most visible campaign to inspire organ, eye and tissue donation, The Donate Life Rose Parade® float inspires viewers to help the over one million people in need of organ, eye or tissue transplants each year. Register today to become an organ, eye or tissue donor by visiting DonateLife.net
For additional information about the Tournament of Roses please visit the official website at www.tournamentofroses.com.
About Xtant Medical
Xtant Medical Holdings, Inc. (NYSE American:XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
About Donate Life America
Donate Life America is a 501(c)3 not-for-profit alliance of national organizations and state teams across the United States committed to increasing organ, eye and tissue donation. Donate Life America manages and promotes the national brand for donation, Donate Life, and assists Donate Life State Teams and national partners in facilitating high-performing donor registries; developing and executing effective multi-media donor education programs; and motivating the American public to register now as organ, eye and tissue donors.
Important Cautions Regarding Forward-looking Statements
This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability to comply with covenants in the Company’s senior credit facility and to make deferred interest payments; the ability to maintain sufficient liquidity to fund operations; the ability to remain listed on the NYSE MKT; the ability to obtain financing on reasonable terms; the ability to increase revenue; the ability to continue as a going concern; the ability to maintain sufficient liquidity to fund operations; the ability to achieve expected results; the ability to remain competitive; government regulations; the ability to innovate and develop new products; the ability to obtain donor cadavers for products; the ability to engage and retain qualified technical personnel and members of the Company’s management team; the availability of Company facilities; government and third-party coverage and reimbursement for Company products; the ability to obtain regulatory approvals; the ability to successfully integrate recent and future business combinations or acquisitions; the ability to use net operating loss carry-forwards to offset future taxable income; the ability to deduct all or a portion of the interest payments on the notes for U.S. federal income tax purposes; the ability to service Company debt; product liability claims and other litigation to which we may be subjected; product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights; infringement and ownership of intellectual property; the ability to remain accredited with the American Association of Tissue Banks; influence by Company management; the ability to pay dividends; and the ability to issue preferred stock; and other factors.
Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Investor Contact CG CAPITAL Rich Cockrell 877.889.1972 [email protected] Company Contact Xtant Medical Molly Mason [email protected]


Anta Sports Expands Global Footprint With Strategic Puma Stake
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Washington Post Publisher Will Lewis Steps Down After Layoffs
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Samsung Electronics Shares Jump on HBM4 Mass Production Report
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



